InnovaRx Innova Health Strategies

B52.0

Plasmodium malariae malaria with nephropathy

Billable FY2026 2025-10-01 → 2026-09-30
Exclusions 9 never code together
B52code
Excludes1
  • Plasmodium falciparum (B50.-)B50.-
  • Plasmodium vivax (B51.-)B51.-
B50-B64block
Excludes1
  • amebiasis (A06.-)A06.-
  • other protozoal intestinal diseases (A07.-)A07.-
A00-B99chapter
Excludes1
  • certain localized infections - see body system-related chapters
Excludes2
  • carrier or suspected carrier of infectious disease (Z22.-)Z22.-
  • infectious and parasitic diseases complicating pregnancy, childbirth and the puerperium (O98.-)O98.-
  • infectious and parasitic diseases specific to the perinatal period (P35-P39)P35-P39
  • influenza and other acute respiratory infections (J00-J22)J00-J22

Excludes1 — never code together. The excluded condition and this one are mutually exclusive.

Excludes2 — not included here, but the patient may have both. Code both when documented.

Instructional notes 3
B52code
Includes
  • mixed infections of Plasmodium malariae with other Plasmodium species, except Plasmodium falciparum and Plasmodium vivax
A00-B99chapter
Includes
  • diseases generally recognized as communicable or transmissible
Use additional code
  • code to identify resistance to antimicrobial drugs (Z16.-)Z16.-
Index entries leading here 4
  • Disorder (of) — see also Disease
  • Malaria, malarial (fever) B54
  • Glomerulonephritis N05.9
    • in (due to)
      • Plasmodium malariae B52.0
  • Nephrosis, nephrotic (Epstein's) (syndrome) (congenital) N04.9
    • in
      • malaria (malariae) B52.0
    • malarial (malariae) B52.0
Alongside this code 2 same parent — B52
Additional references
AHA Coding Clinic® Licence required

Official coding advice for this code. Published by the American Hospital Association. Not included in this installation.

Risk adjustment

ESRD21HCC141

Presence is a property of the code. Untick a model to hide it everywhere.

This code

Billable
yes
Code set
FY2026
Parent
B52
Block
B50-B64
Siblings
2

Present FY2024–FY2027.